Mercanto Holdings earns $177,785 in Q2

Executive Summary

• Mercanto Holdings Inc. reported its unaudited consolidated financial results for the second quarter of fiscal 2026 (period ended Jan. 31, 2026), showing significant year-over-year growth in revenue and profitability.
• The company achieved positive EBITDA and net income for the first time in the comparable prior-year period, while maintaining a debt-free balance sheet (excluding lease liabilities).
• Commercially, the company provided updates on its Quebec market strategy, including the upcoming launch of new CBD capsule formats and infused preroll products.

Key Details

• Revenue: $2,076,820 for Q2 2026, an increase of 107% compared to $1,003,116 in the prior-year period.
• Gross Profit: $464,845 for Q2 2026, an increase of 137% compared to $196,413 in the prior-year period.
• EBITDA: $252,233 for Q2 2026, representing a swing from a negative $96,038 in the prior-year period (an improvement of $348,271).
• Net Income: $177,785 for Q2 2026, compared to a net loss of $109,215 in the prior-year period (an improvement of $287,000).
• Balance Sheet: The company has no long-term debt other than lease liabilities and is current on all cannabis excise tax obligations.
• Share Count: 51,674,683 common shares outstanding as of the release date.
• Product Launch (CBD Capsules): A new CBD 10-milligram capsule format (30 capsules per container) is scheduled for in-store introduction in August 2026. This complements existing CBD 50 mg and 100 mg capsules.
• Online Assortment: By August 2026, the full four-SKU CBD capsule assortment (10 mg, 25 mg, 50 mg, and 100 mg) is expected to be available on the Quebec government's cannabis e-commerce platform.
• Product Launch (Infused Prerolls): An infused preroll product is scheduled for launch in June 2026 to expand presence in the infused derivative category.

Notable Quotes

• No direct quotes from the CEO or President were included in the provided text.